5-11-16/Breast Cancer Research: “Phosphatidylserine-targeting Antibodies Augment the Anti-Tumorigenic Activity of Anti-PD-1 Therapy by Enhancing Immune Activation & Downregulating Pro-Oncogenic Factors Induced by T-Cell Checkpoint Inhibition in Murine Triple-Negative Breast Cancers” http://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-016-0708-2